Sugi Predict

Sugi Predict / Compounds / SCHEMBL7110522

SCHEMBL7110522

SCHEMBL7110522

CC(=O)c1ccc2c(c1)oc1ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 7/20 0.69
▸ RAB9A P51151 7/20 0.69
▸ TTR P02766 2/20 0.61
▸ HTR2B P41595 1/20 0.59
▸ SMN1; SMN2 Q16637 6/20 0.55
▸ MEN1 O00255 5/20 0.55
▸ KMT2A Q03164 5/20 0.55
▸ GAA P10253 2/20 0.55
▸ ALDH1A1 P00352 5/20 0.54
▸ HPGD P15428 5/20 0.54
▸ MAPT P10636 5/20 0.54
▸ HSD17B10 Q99714 3/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ LMNA P02545 2/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ HTT P42858 2/20 0.50
▸ AHR P35869 1/20 0.50
▸ ATM Q13315 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26304441 0.97 NPC1 (0.65) NPC1RAB9ATTRHTR2BSMN1; SMN2
SCHEMBL26304467 0.92 NPC1 (0.68) NPC1RAB9ATTRHTR2BSMN1; SMN2
SCHEMBL26317302 0.92 NPC1 (0.59) NPC1RAB9ATTRHTR2BSMN1; SMN2
SCHEMBL15040999 0.91 NPC1 (0.54) NPC1RAB9ATTRHTR2BSMN1; SMN2
SCHEMBL26304440 0.90 NPC1 (0.74) NPC1RAB9ATTRHTR2BSMN1; SMN2
SCHEMBL30765635 0.89 NPC1 (0.79) NPC1RAB9ATTRHTR2BSMN1; SMN2
SCHEMBL1283826 0.89 NPC1 (0.79) NPC1RAB9ATTRHTR2BSMN1; SMN2
SCHEMBL26317209 0.88 NPC1 (0.72) NPC1RAB9ATTRHTR2BSMN1; SMN2
SCHEMBL26317339 0.88 NPC1 (0.59) NPC1RAB9ATTRHTR2BSMN1; SMN2
SCHEMBL26304575 0.88 NPC1 (0.59) NPC1RAB9ATTRHTR2BSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 — — CN disclosed
CN-114981251-B Dibenzofuran derivative cathepsin K inhibitor and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2023-11-21 — — CN disclosed
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 — — WO disclosed
CN-115433120-A Spirofluorene derivative containing seven-membered ring, electron transport material and organic electroluminescent device 常州强力昱镭光电材料有限公司 2022-12-06 — — CN disclosed
CN-114981251-A Diphenyl furan derivative cathepsin K inhibitor and preparation method and medical application thereof 深圳信立泰药业股份有限公司 2022-08-30 — — CN disclosed
CN-102731282-B Method for extracting dibenzofuran from absorber oil of coal tar HAN ZHAOWU 2014-08-13 — — CN disclosed
CN-102731282-A Method for extracting dibenzofuran from absorber oil of coal tar ZHAOWU HAN 2012-10-17 — — CN disclosed
EP-0882707-B1 NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME ASAHI CHEMICAL IND (JP) 2003-10-08 — — EP disclosed
US-20030139475-A1 Novel tricyclic compounds and drug compositions containing same ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2003-07-24 — — US disclosed
US-6545053-B1 Aminoethoxyfluorene derivatives are beta-3 adrenaline receptor agonists and are useful as drugs for the treatment and prevention of diabetes, obesity, hyperlipemia, etc. ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2003-04-08 — — US disclosed
US-6187809-B1 BETA-3 ADRENALINE RECEPTOR AGONIST DRUGS FOR THE TREATMENT OF DIABETES, OBESITY, AND HYPERLIPEMIA; 2-(N-(2-(DIBENZOFURAN-3-YLOXY)ETHYL)AMINO)-1-PHENYLETHANOL, FOR EXAMPLE ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2001-02-13 — — US disclosed
US-6037362-A CARBAZOLE DERIVATIVES; DEPROTECTING, AMINATION; ANTILIPEMIC AND ANTIDIABETIC AGENTS; B-ADRENALINE RECEPTOR AGONISTS; DIETETICS ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) 2000-03-14 — — US disclosed
EP-0882707-A1 NOVEL TRICYCLIC COMPOUNDS AND DRUG COMPOSITIONS CONTAINING THE SAME Asahi Kasei Kogyo Kabushiki Kaisha (JP) 1998-12-09 — — EP disclosed
EP-0422079-A4 TRICYCLIC LIPOXYGENASE INHIBITING COMPOUNDS, COMPOSITIONS, METHODS OF USE — 1991-08-21 — — EP disclosed
EP-0422079-A1 TRICYCLIC LIPOXYGENASE INHIBITING COMPOUNDS, COMPOSITIONS, METHODS OF USE ABBOTT LABORATORIES (US) 1991-04-17 — — EP disclosed
WO-1989012636-A1 TRICYCLIC LIPOXYGENASE INHIBITING COMPOUNDS, COMPOSITIONS, METHODS OF USE ABBOTT LABORATORIES (US) 1989-12-28 — — WO disclosed
EP-0346939-A1 Tricyclic lipoxygenase inhibiting compounds ABBOTT LABORATORIES (US) 1989-12-20 — — EP disclosed
US-4822811-A Carbazole lipoxygenase inhibiting compounds, compositions and use ABBOTT LABORATORIES (US) 1989-04-18 — — US disclosed
US-4769387-A Dibenzofuran lipoxygenase inhibiting compounds, compositions and use ABBOTT LABORATORIES (US) 1988-09-06 — — US disclosed
US-4251341-A DIALKOXY-ACETYL DERIVATIVES OF AROMATIC COMPOUNDS CIBA-GEIGY CORPORATION (US) 1981-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139475-A1 Novel tricyclic compounds and drug compositions containing same ADRB3, MC2R, NR3C1 NPC1 586/4885RAB9A 2324/4885TTR 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.